London-listed blood disease specialist Hemogenyx Pharmaceuticals (LSE: HEMO) has signed a license agreement with US pharma major Eli Lilly (NYSE: LLY).
Early market reaction was positive, with Hemogenyx’ shares rising almost 7% to 2.51 pence, but the stock was down 5.5% at 2.22 pence by close of London trading.
Under this accord, Lilly grants the UK company an exclusive worldwide license to certain intellectual property developed by Lilly (IP) related to a CDX bispecific antibody for all uses, including the treatment of acute myeloid leukemia (AML) and other blood cancers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze